Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Concord Biotech Limited's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.775398
debtToEquity 0.088000
earningsGrowth -0.163000
revenueGrowth 0.137000
grossMargins 0.639150
operatingMargins 0.288850
trailingEps 29.750000
forwardEps 41.004060

CONCORDBIO's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
CONCORDBIO's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.
Concord Biotech Limited's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
CONCORDBIO's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with CONCORDBIO anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

Concord Biotech Limited's present price, in relation to its projections, shows no obvious risks or opportunities. This neutral outlook suggests stability, where investors might consider waiting for more decisive signals before making any significant moves.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


Analysts have shown a buy bias for Concord Biotech Limited, marking it as a favorable investment option. This could inspire investors to see Concord Biotech Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.